Jasper Therapeutics Inc.
JSPR evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for JSPR—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · JSPR
Jasper Therapeutics Inc. is a clinical-stage biotechnology company focused on developing therapies for inflammatory and fibrotic diseases, currently advancing its lead candidate through Phase 3 trials while facing significant financing needs and a history of operating losses.
Key risk: Cash runway insufficient
BioSniper Score
Based on 6 of 6 signals
Market Cap
$23.3M
Cash Runway
3.9 moLead Asset
briquilimab (Phase 1)Next Catalyst
Phase3_Topline · Jun 30, 2029Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 17 clinical trials · 1 catalyst for Jasper Therapeutics Inc..
Jasper Therapeutics Inc. is a clinical-stage biotechnology company focused on developing therapies for inflammatory and fibrotic diseases, currently advancing its lead candidate through Phase 3 trials while facing significant financing needs and a history of operating losses.
- As of June 30, 2026, Jasper Therapeutics had cash and equivalents of $7.7M and shareholders' equity of $4.2M, with a net loss of $2.8M for the period [sec].
- The company raised approximately $132.0 million in gross proceeds on July 20, 2026 from the issuance of non-voting convertible preferred stock in connection with the Kira acquisition [sec_mda · as of 2026-08-14].
- Jasper has an accumulated deficit of $307.6 million as of September 30, 2025 [sec_mda · as of 2025-11-10].
- The company's primary use of cash is for research and development, and it expects to continue incurring significant expenses as it advances its product candidates [sec_mda · as of 2026-08-14].
What works
- Jasper raised substantial capital through a $132.0 million gross proceeds from convertible preferred stock issuance in July 2026, bolstering its financial position [sec_mda · as of 2026-08-14].
- The company has access to additional financing sources, including $93.5 million allocated under the ATM Prospectus and $170.0 million available under the Shelf Registration Statement as of June 30, 2026 [sec_mda · as of 2026-08-14].
- Jasper is advancing its lead product candidate into Phase 3 clinical trials, indicating progress in its development pipeline [catalyst_timeline].
What to weigh
- Jasper has a history of operating losses, with an accumulated deficit of $307.6 million as of September 30, 2025, and no revenue from commercial product sales [sec_mda · as of 2025-11-10].
- The company's cash and cash equivalents of $7.7M as of June 30, 2026 are not sufficient to fund operations for at least twelve months, requiring additional capital [sec] [sec_mda · as of 2026-05-14].
- Jasper faces significant uncertainty in obtaining adequate financing, which could force delays or reductions in its research and development programs [sec_mda · as of 2026-08-14].
- The company may never achieve profitability and depends on successful development, approval, and commercialization of its product candidates [sec_mda · as of 2026-05-14].
From the filings
Quoted directly from source documents.
Jasper raised $132.0 million from convertible preferred stock issuance in July 2026.
“we received approximately $132.0 million gross proceeds on July 20, 2026 from the issuance of 4,655,951 shares of non-voting convertible preferred stock to investors”
SEC MD&A · August 14, 2026
Jasper has an accumulated deficit of $307.6 million as of September 30, 2025.
“As of September 30, 2025, we had an accumulated deficit of $307.6 million”
SEC MD&A · November 10, 2025
Jasper's cash is insufficient to fund operations for twelve months.
“our current cash and cash equivalents will not be sufficient to fund our ongoing operations for a period of at least twelve months from the date the condensed consolidated financial statements included in this Quarterly Report on Form 10-Q are issued”
SEC MD&A · May 14, 2026
Jasper has access to $93.5 million under ATM and $170.0 million under Shelf Registration.
“As of June 30, 2026, $93.5 million remains allocated and available under the ATM Prospectus and $170.0 million remains available and unallocated under the Shelf Registration Statement”
SEC MD&A · August 14, 2026
Catalyst timeline
- 2029-06-30 · Phase3_Topline — Topline results from Phase 3 trial of exercise-based smoking cessation treatment for adults with high anxiety.
Risks & what to watch (4)›
Key risks
- Cash runway insufficient — Cash and equivalents of $7.7M as of June 30, 2026 are not enough to fund operations for 12 months [sec] [sec_mda · as of 2026-05-14].
- History of operating losses — Accumulated deficit of $307.6M as of September 30, 2025, with no commercial revenue [sec_mda · as of 2025-11-10].
- Dependence on future financing — Inability to obtain adequate financing may force delay or elimination of R&D programs [sec_mda · as of 2026-08-14].
- Profitability uncertain — Company may never achieve profitability; depends on successful development and approval of product candidates [sec_mda · as of 2026-05-14].
What to watch
- Phase 3 topline data expected on June 30, 2029 for the lead candidate [catalyst_timeline].
- Ability to secure additional financing to extend cash runway beyond current levels [sec_mda · as of 2026-08-14].
- Progress in research and development programs and any updates on clinical trial timelines [sec_mda · as of 2026-08-14].
Sources: SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run Jasper Therapeutics Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Jasper Therapeutics Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
3.9 months
D/E 7.35 · 0% dilution
Lead: Phase 1
1 candidate
1 upcoming, next in ~1035d
2 buys · 0 sells (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
56
Total value held
$11.3M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 2,345,194 | $2.1M |
| millennium management llc | 1,617,531 | $1.4M |
| acorn capital advisors, llc | 1,411,492 | $1.2M |
| kingdon capital management, l.l.c. | 1,352,106 | $1.2M |
| morgan stanley | 1,333,420 | $1.2M |
| rock springs capital management lp | 1,100,726 | $964K |
| boothbay fund management, llc | 582,751 | $511K |
| jacobs levy equity management, inc | 322,273 | $282K |
| geode capital management, llc | 317,677 | $278K |
| bank of america corp /de/ | 293,259 | $257K |
Showing top 10 of 56 institutional holders of Jasper Therapeutics Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 30, 2026- % of float
- 9.8%
- Days to cover
- 4.7
- Shares short
- 2,730,146
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
JSPR short interestGovernance
Frequently asked questions
What is the AI investment thesis for Jasper Therapeutics Inc.?
Jasper Therapeutics Inc. is a clinical-stage biotechnology company focused on developing therapies for inflammatory and fibrotic diseases, currently advancing its lead candidate through Phase 3 trials while facing significant financing needs and a history of operating losses.
What is Jasper Therapeutics Inc.'s lead drug candidate?
Jasper Therapeutics Inc.'s most advanced tracked candidate is briquilimab (Phase 1) for Chronic Inducible Urticaria; Chronic Spontaneous Urticaria; Urticaria Chronic.
What is Jasper Therapeutics Inc.'s next catalyst?
Jasper Therapeutics Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: Efficacy and Implementation of Exercise-based Smoking Cessation Treatment for Adults With High Anxie" — expected June 30, 2029.
Who is the CEO of Jasper Therapeutics Inc.?
Mr. Jeetinder Singh Mahal M.B.A. is the chief executive officer of Jasper Therapeutics Inc. (JSPR).
Where is Jasper Therapeutics Inc. headquartered?
Jasper Therapeutics Inc. (JSPR) is headquartered in Redwood City, CA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.